CoreCap Advisors’s Theravance Biopharma TBPH Stock Holding History

CoreCap Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27	Closed	-$241	–	3215
2025 Q1	$241	Buy	+27	New	+$251	﹤0.01%	2892

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CoreCap Advisors's TBPH Position: Q2 2025 in Review

CoreCap Advisors sold out of Theravance Biopharma (TBPH) in Q2 2025, closing a stake of 27 shares — an estimated $241 sold.

CoreCap Advisors first reported a position in TBPH in Q1 2025 and held it in 1 quarter. The position peaked at $241 in Q1 2025. 135 funds tracked by Wall St. Rank hold TBPH as of Q2 2025.

CoreCap Advisors reported no remaining Theravance Biopharma position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 27 Theravance Biopharma shares in Q2 2025, an estimated $241.
CoreCap Advisors first reported a position in Theravance Biopharma in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's Theravance Biopharma position peaked at $241 in Q1 2025.
135 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.